EP2192174A1 - Umprogrammierung von Zellen zu einem pluripotenten Status - Google Patents

Umprogrammierung von Zellen zu einem pluripotenten Status Download PDF

Info

Publication number
EP2192174A1
EP2192174A1 EP08400048A EP08400048A EP2192174A1 EP 2192174 A1 EP2192174 A1 EP 2192174A1 EP 08400048 A EP08400048 A EP 08400048A EP 08400048 A EP08400048 A EP 08400048A EP 2192174 A1 EP2192174 A1 EP 2192174A1
Authority
EP
European Patent Office
Prior art keywords
cells
reprogramming
cell
process according
reprogrammed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08400048A
Other languages
English (en)
French (fr)
Other versions
EP2192174B1 (de
Inventor
Alexandra Dr. Stolzing
Antje Arnold
Jeremy Dr. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority to ES08400048.8T priority Critical patent/ES2561949T3/es
Priority to EP08400048.8A priority patent/EP2192174B1/de
Priority to EP14192115.5A priority patent/EP2881461A1/de
Priority to US13/130,093 priority patent/US20110236978A1/en
Priority to PCT/EP2009/008170 priority patent/WO2010057614A1/en
Priority to JP2011536768A priority patent/JP2012509072A/ja
Publication of EP2192174A1 publication Critical patent/EP2192174A1/de
Application granted granted Critical
Publication of EP2192174B1 publication Critical patent/EP2192174B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Definitions

  • the present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.
  • IPS Induced Pluripotent Stem Cells
  • Another approach employs contacting cells to be reprogrammed with extracts of human embryonic stem cells for reprogramming cells. This approach, however, is ethically and practically problematic.
  • the technical problem underlying the present invention is to provide improved methods to reprogram cells, in particular to dedifferentiate cells, which overcome the above-identified disadvantages, in particular allow in an easy, efficient and safe way the provision of reprogrammed, in particular dedifferentiated cells, preferably displaying multipotent, most preferably pluripotent, stem cell character.
  • the present invention solves its technical problem by the provision of a process for preparing reprogrammed cells in vitro, comprising the process steps, preferably in the given order, a) providing cells to be reprogrammed; b) introducing, preferably transfecting, mRNA molecules capable of reprogramming the cells into the cells provided in step a), wherein the reprogramming mRNA molecules are coding for at least one protein selected from the group consisting of: Ronin, Oct4, Klf4, Sox2, Nanog and TERT; and c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the introduced, preferably transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.
  • the present invention foresees a process which is able to prepare reprogrammed cells without the need to permanently change the genome of the cell and without the need to use viruses to transfer transcription factors or the like into the cell.
  • the present invention also is advantageous in so far, as for reprogramming cells no extracts of human embryonic stem cells or cost intensive and potentially dangerous chemical factors are needed. Thus, ethical concerns, genetic stability problems and cancer risks are reduced or even avoided.
  • the present invention provides the advantageous teaching to introduce, preferably transfect, specific mRNA molecules, in the following termed "reprogramming mRNA molecules", into the cells, wherein these reprogramming mRNA molecules are able to reprogram the mRNA recipient cells, preferably the cells being transfected therewith, into a dedifferentiated status.
  • the mRNA molecules introduced, preferably transfected, according to the present invention will not integrate into the recipient's genome and therefore do not pose a risk of cancer or genetic instability.
  • the invention therefore foresees a process for preparing one or more reprogrammed cells in vitro wherein said process does not include any cloning amplification or proliferation of the mRNA recipient cells.
  • the present invention also foresees a process for preparing one or more reprogrammed cells in vivo, that is in a living organ, a living organism or animal, more particular a mammal.
  • reprogramming preferably means remodelling, in particular erasing and/or remodelling, epigenetic marks of a cell such as DNA methylation, histon methylation or activating genes by inducing transcription factor signal systems as for oct4.
  • the reprogramming of the present invention provides at least one dedifferentiated and/or rejuvenated cell, in particular provides a cell having the characteristic of a multipotent, in particular pluripotent stem cell.
  • the present invention is able to maintain these cells by the reprogramming of the present invention in their multi- or pluripotent state for a prolonged period of time.
  • the present invention allows the dedifferentiation into a multipotent or pluripotent stem cell.
  • multipotent cells may be reprogrammed to become pluripotent cells.
  • reprogrammed cells designates cells which have been changed to have a higher differentiation and/or proliferation potential.
  • reprogramming of a somatic differentiated cell toward a multipotent stem cell or "young" differentiated cell is termed reprogramming and the product is called a reprogrammed cell.
  • the present process allows it to enrich immature stem cells, preferably showing a high telomerase activity, several multipotent, preferably pluripotency, markers and an increased secretion of growth factors.
  • the present invention provides the advantage that aged stem cells can be expanded for a longer period of time and with a higher stem cell yield. Further, stem cell lines and tissue engineered construct drafts made or derived from cells reprogrammed by the present process show a reduced minimal immunological risk, in particular if the patient owns cells are used as a source for the reprogramming.
  • the present invention provides means and methods to prepare in particular pluripotent stem cells, to provide multipotent stem cells, to provide means and methods for an increased expansion of cells or stem cells in vitro and for the rejuvenation of aged cells or aged stem cells for tissue engineering or cell therapies.
  • the present invention foresees, preferably in a first step, to provide cells to be reprogrammed.
  • the cells to be reprogrammed may be adult, neonatal or embryonic differentiated cells, but are not limited thereto.
  • the cells to be reprogrammed are adult or neonatal undifferentiated cells. All of these cells may, in a preferred embodiment, be cell lines, immortalized cells, cells kept in cell culture, isolated cell populations, preferably cells isolated from a donor, either a living or dead donor, or cells isolated from the environment.
  • Cell types which can be reprogrammed according to the present invention potentially are all cell types, and are in preferred instances fibroblasts, hepatocytes, cardiac cells, cardiomyocytes, nerve cells, chondrocytes, osteoblasts, adipocytes, myoblasts, hepatoblasts, hepatic stem cells, insulin producing cells, neural stem cells, cardiomyogenic cells, dermatocytes, keratinocytes, pancreatic cells, monocytes, epithelial cells or mesenchymal stem cells (MSC).
  • the cells may be mammalian cells, in particular human cells or animal cells, preferably ovine, horse, ape or in particular rodent cells, preferably hamster cells, mouse cells or rat cells.
  • the cells may also be fish, reptile, avian, amphibian or insect cells.
  • the cells to be reprogrammed are lineage-committed cells.
  • the cells, in particular the cells of the above identified origin are stem cells, in particular post-natal stem cells or non-embryonic stem cells.
  • a suitable and preferred stem cell source like mesenchymal stem cells is a tissue within the human or animal body which comprises the stem cells for use in the present invention, optionally together with other cell types.
  • the suitable stem cell source is bone marrow, both adult and fetal, cytokine or chemotherapy mobilized peripheral blood, fetal liver, umbilical cord blood, embryonic yolk sac and spleen, both adult and fetal, more preferably the stem cell source is adult bone marrow or umbilical cord blood, most preferably the stem cell source is bone marrow.
  • Bone marrow cells may be obtained from any known source, including, but not limited to, ilium, sternu, tibiae, femora, spine or other bone cavities.
  • the stem cells are isolated from a mammalian organism such as human, mouse or rat, and more preferably the stem cells are isolated from a human organism.
  • isolated cell population is intended to mean that the cells are not in contact with other cells with which they are usually in contact within the body of the mammal or in a tissue sample obtained directly, i.e. without purification or enrichment step, from the mammal.
  • a "cell population” according to the present invention may comprise not only cells of one cell type such as fibroblasts s or mesenchymal stem cells as defined for example by the expression of a specific combination of surface markers, but also a mixture of cells of different cell types which show different combinations of surface markers.
  • the cells harvested from said sources may be used directly for transfection or may be cryoconserved by freezing them at a temperature from about - 196 °C to about - 130°C.
  • the cells to be reprogrammed receive, according to the present invention, in a second step at least one species of reprogramming mRNA molecules, in particular linear and isolated mRNA molecules, selected from the group of mRNA molecules encoding Ronin, mRNA molecules encoding Oct4, mRNA molecules encoding Klf4, mRNA molecules encoding Sox2, mRNA molecules encoding Nanog and mRNA molecules encoding TERT.
  • Ronin, Oct4, Klf4, Sox2, Nanog and TERT are proteins with the ability to reprogram cells.
  • these proteins are termed "reprogramming proteins" and are characterised by their ability to reprogram target cells and therefore by their regulatory function in terms of determining the cell fate, in particular being able to dedifferentiate a target cell and/or maintain a cell in a dedifferentiated state, preferably by being transcription factors.
  • Differentiation behaviour of cells and state of differentiation can be detected according to the methods set forth below. However any method for determining the differentiation state or potency of a cell known the skilled person are applicable as well.
  • the cell to be reprogrammed is transfected with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is supplemented with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is injected with one or more reprogramming mRNA molecules according to the present invention.
  • the present invention thus foresees to use one or more of mRNA molecules encoding Ronin, Oct4, Klf4, Sox2, Nanog or TERT.
  • These mRNA molecules may, in a preferred embodiment, be molecules having the wild-type mammalian, in particular human, animal, preferably rodent, more preferably mouse, hamster or rat or any other animal nucleotide sequence.
  • the reprogramming mRNA molecule is selected from the group consisting of mRNA nucleotide sequence molecules being encoded by any one of the DNA sequences given under SEQ ID No. 1 to 16.
  • a functional equivalent is a nucleotide sequence molecule, which either codes with a different nucleotide sequence exactly the same protein as the mRNA sequence encoded by any one of SEQ ID No. 1 to 16 or is a mRNA sequence, which encodes a protein with a different amino acid sequence but with same or similar function, in particular being able to reprogram the cells according to the present invention.
  • the functional equivalent of the mRNA molecules is a polynucleotide with a homologous sequence to the wild-type mRNA polynucleotide as encoded by the DNA sequence in any one of SEQ ID No. 1 to 16.
  • the degree or percentage of homology is at least 50, 60, 70, 80, 90, 95, 99 or 100%.
  • a functional equivalent of the mRNA molecules as given in any one of SEQ ID No. 1 to 16 is a mRNA sequence which is encoded by a DNA sequence being substantially complementary to the sequences of any one of SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence.
  • the functional equivalent of the mRNA molecule as encoded by any one of the DNA sequences of SEQ ID No. 1 to 16 is a mRNA molecules being encoded by a DNA sequence which is able to hybridize under stringent or reduced stringent conditions to any one of the polynucleotides given in SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence.
  • mRNA molecule is meant to refer to a linear polymer of ribonucleotide molecules, which is single-stranged and serves as a template for protein synthesis.
  • Polynucleotides have "homologous" sequences if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence as described herein. Sequence comparison between two or more polynucleotides is generally performed by comparing portions of the two sequences over a comparison window to identify and compare local regions of sequence similarity.
  • the comparison window is generally from about 20 to 200 contiguous nucleotides.
  • the "percentage of sequence homology" for polynucleotides may be determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may include additions or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • the percentage is calculated by: (a) determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions; (b) dividing the number of matched positions by the total number of positions in the window of comparison; and (c) multiplying the result by 100 to yield the percentage of sequence homology.
  • Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms, or by inspection. Readily available sequence comparison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST) ( Altschul, S.F. et al. 1990. J. Mol. Biol. 215:403 ; Altschul, S.F. et al. 1997. Nucleic Acid Res. 25:3389-3402 ) and ClustalW programs both available on the internet. Other suitable programs include GAP, BESTFIT and FASTA in the Wisconsin Genetics Software Package (Genetics Computer Group (GCG), Madison, WI, USA).
  • substantially complementary means that two nucleic acid sequences in question have at least about 65%, preferably about 70%, more preferably about 80%, even more preferably 90%, and most preferably about 98%, sequence complementarity to each other. This means that the DNA sequence coding the functional equivalent and the polynucleotide given in any of SEQ ID No. 1 to 16 or its complement must in a preferred embodiment exhibit sufficient complementarity to hybridise under stringent conditions.
  • a substantially complementary sequence is preferably one that has sufficient sequence complementarity to the nucleotide sequence in question to result in binding.
  • primer refers to an oligonucleotide which is capable of annealing to the amplification target allowing a DNA polymerase to attach thereby serving as a point of initiation of DNA synthesis when placed under conditions in which synthesis of primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH.
  • the (amplification) primer is preferably single stranded for maximum efficiency in amplification.
  • the primer is an oligodeoxy ribonucleotide.
  • the primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primer.
  • a "pair of bi-directional primers" as used herein refers to one forward and one reverse primer as commonly used in the art of DNA amplification such as in PCR amplification.
  • stringency or “stringent hybridization conditions” refer to hybridization conditions that affect the stability of hybrids, e.g., temperature, salt concentration, pH, formamide concentration and the like. These conditions are empirically optimised to maximize specific binding and minimize nonspecific binding of an oligo- or polynucleotide to its target nucleic acid sequence.
  • the terms as used include reference to conditions under which a an oligo- or polynucleotide will hybridise to its target sequence, to a detectably greater degree than other sequences (e.g. at least 2-fold over background). Stringent conditions are sequence dependent and will be different in different circumstances. Longer sequences hybridise specifically at higher temperatures.
  • stringent conditions are selected to be about 5 DEG C (degree celcius) lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
  • Tm is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridises to a perfectly matched oligo- or polynucleotide.
  • stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ⁇ +> ion, typically about 0.01 to 1.0 M Na ⁇ +> ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 DEG C for short probes or primers (e.g. 10 to 50 nucleotides) and at least about 60 DEG C for long probes or primers (e.g. greater than 50 nucleotides).
  • Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
  • Exemplary low stringent conditions or “conditions of reduced stringency” include hybridization with a buffer solution of 30% formamide, 1 M NaCl, 1% SDS at 37 DEG C and a wash in 2x SSC at 40 DEG C.
  • Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37 DEG C, and a wash in 0.1x SSC at 60 DEG C.
  • Hybridization procedures are well known in the art and are described in e.g. Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994 .
  • the present invention foresees to introduce, preferably transfect, specific reprogramming mRNA molecules into the cells, which mRNA molecules once introduced, preferably transfected, in the cells are able to be translated into so called reprogramming proteins which can turn on specific genes in the cells, in particular multipotency and/or the pluripotency genes in the cell.
  • the mRNA molecule used according to the present invention is preferably a linear molecule having a poly A tail, most preferably produced by in vitro transcription.
  • the mRNA molecules are produced by in vitro transcription, in particular using bacterial systems.
  • the DNA sequences of the reprogramming proteins are cloned into plasmids and amplified in bacteria, for instance E. coli.
  • the plasmids are then isolated from the bacteria, are linearised and subjected to restriction digestion.
  • cDNA prepared by said method is transcribed into mRNA, which in turn is incubated to destroy cDNA residues and to obtain mRNA molecules to be introduced into the cells.
  • the present teaching foresees to introduce, preferably transfect, the reprogramming mRNA molecules into the cell by electroporation, by lipofection, by injection, by magnetofection, by particle bombardment, gene gun, or by any other method known in the art suitable to introduce mRNA molecules into a target cell.
  • the present invention further foresees in its step c) to culture the cells into which the reprogramming mRNA molecules have been introduced in a cell culture medium and under a condition suitable to allow translation of the transfecting reprogramming mRNA molecules, so as to obtain the reprogrammed cells.
  • the present process therefore consists of the above-identified steps a), b) and c), preferably in this order. Accordingly, the present invention excludes any further process steps, in particular any further substantial process step, in particular any intervening or subsequent process steps. Thus, the present invention provides its advantages in a simple and cost-effective way.
  • the cell culture system is a cell culture system, comprising a cell culture medium, preferably in a culture vessel, in particular a cell culture medium supplemented with at least one so called "inducing substance", which is a substance suitable and determined for protecting the cells from in vitro aging and/or inducing in an unspecific or specific reprogramming.
  • an inducing substance according to the present invention is a substance selected from the group consisting of reversin, resveratol, selenium, a selenium-containing compound, EGCG ((-)-epigallocatechin-3-gallate), valporic acid and salts of valporic adic, in particular sodium valporat.
  • the at least one inducing substance is present in the cell culture medium used in step c) of the present process in a concentration from 0.001 to 100 ⁇ M, preferably from 0.005 to 50 ⁇ M.
  • the present invention foresees to use a concentration of reversin from 0.5 to 10 ⁇ M, preferably of 1 ⁇ M. In a furthermore preferred embodiment the present invention foresees to use resveratrol in a concentration of 10 to 100 ⁇ M, preferably 50 ⁇ M. In a furthermore preferred embodiment the present invention foresees to use selenium or a selenium containing compound in a concentration from 0.05 to 0.5 ⁇ M, preferably of 0.1 ⁇ M. In furthermore preferred embodiment the present invention foresees to use EGCG in a concentration from 0.001 to 0.1 ⁇ M, preferably of 0.01 ⁇ M. In a furthermore preferred embodiment the present invention foresees to use valpouric acid or sodium valporate in a concentration from 1 to 10 ⁇ M, in particular of 5 ⁇ M.
  • the present invention foresees in a furthermore preferred embodiment culturing the cells obtained in step b) in a cell culture medium, wherein the cell culture medium comprises, optionally in combination with the inducing substance as specified above, at least one transient proteolysis inhibitor.
  • the use of at least one proteolysis inhibitor in the cell culture medium of the present invention increases the time the reprogramming proteins derived from the mRNA or any endogenous genes will be present in the cells and thus facilitates in an even more improved way the reprogramming by the transfected mRNA derived factors.
  • the present invention uses in a particularly preferred embodiment as a transient proteolysis inhibitor a protease inhibitor, a proteasome inhibitor and/or a lysosome inhibitor.
  • the proteosome inhibitor is selected from the group consisting of MG132, TMC-95A, TS-341 and MG262.
  • the protease inhibitor is selected from the group consisting of aprotinin, G-64 and leupeptine-hemisulfat.
  • the lysosomal inhibitor is ammonium chloride.
  • the present invention also foresees a cell culture medium comprising at least one transient inhibitor of mRNA degradation.
  • a transient inhibitor of mRNA degradation increases the half-life of the reprogramming factors as well.
  • a condition suitable to allow translation of the transfected reprogramming mRNA molecules in the cells is an oxygen content in the cell culture medium from 0.5 to 21%, preferably from 1 to 20%, more preferably from 5 to 19% and particularly preferred from 10 to 18%. More particular, and without wishing to be bound to the theory, oxygen is used to further induce or increase Oct4 by triggering Oct4 via Hif1a.
  • conditions that are suitable to support reprogramming of the cells by the mRNA molecules in the cells are selected; more particularly, these conditions require a temperature from 30 to 38°C, preferably from 31 to 37°C, most preferably from 32 to 36°C.
  • the glucose content of the medium is in a preferred embodiment of the present invention below 4.6 g/l, preferably below 4.5 g/l, more preferably below 4 g/l, even more preferably below 3 g/l, particularly preferably below 2 g/l and most preferably it is 1 g/l.
  • DMEM media containing 1 g/l glucose being preferred for the present invention are commercially available as "DMEM low glucose" from companies such as PAA, Omega Scientific, Perbio and Biosera. More particular, and without wishing to be bound to the theory, high glucose conditions adversely support aging of cells (methylation, epigenetics) in vitro which may render the reprogramming difficult.
  • the cell culture medium contains glucose in a concentration from 0.1 g/I to 4.6 g/l, preferably from 0.5 g/l to 4,5 g/l and most preferably from 1 g/I to 4 g/l.
  • cell culture and “culturing of cells” refer to the maintenance and propagation of cells and preferably human, human-derived and animal cells in vitro.
  • Cell culture medium is used for the maintenance of cells in culture in vitro. For some cell types, the medium may also be sufficient to support the proliferation of the cells in culture.
  • a medium according to the present invention provides nutrients such as energy sources, amino acids and anorganic ions. Additionally, it may contain a dye like phenol red, sodium pyruvate, several vitamins, free fatty acids, antibiotics, anti-oxidants and trace elements.
  • any standard medium such as Iscove's Modified Dulbecco's Media (IMDM), alpha-MEM, Dulbecco's Modified Eagle Media (DMEM), RPMI Media and McCoy's Medium is suitable before reprogramming.
  • IMDM Iscove's Modified Dulbecco's Media
  • alpha-MEM alpha-MEM
  • RPMI Media Dulbecco's Modified Eagle Media
  • McCoy's Medium McCoy's Medium
  • the medium additionally comprises one or more additives selected from the group consisting of vitamin D3 (1,25-dihydroxyvitamin D3, quetriol), resveratrol (trans-3, 4', 5-trihydroxystilbene), reversine (2-(4-morpholinoanilino)-N6-cyclohexyladenine), vitamin E (RRR- ⁇ -tocopherol), valproic acid (dekapene, valproate, valrelease), EGCG (epigallocatechin-3-gallat) and selenium.
  • additives selected from the group consisting of vitamin D3 (1,25-dihydroxyvitamin D3, quetriol), resveratrol (trans-3, 4', 5-trihydroxystilbene), reversine (2-(4-morpholinoanilino)-N6-cyclohexyladenine), vitamin E (RRR- ⁇ -tocopherol), valproic acid (dekapene, valproate, valrelease), EGCG (epigalloc
  • two of the afore-mentioned additives are present, more preferably three of the afore-mentioned additives are present, even more preferably four of the afore-mentioned additives are present, particularly preferably five of the afore-mentioned additives are present and most preferably all of the afore-mentioned additives are present.
  • the medium may in a particular embodiment further comprise a serum component such as horse serum, human serum or fetal calf serum (FCS).
  • a serum component such as horse serum, human serum or fetal calf serum (FCS).
  • FCS fetal calf serum
  • the medium contains FCS.
  • the serum is present in a concentration of 1-20%, preferably of 3-18%, more preferably of 5-15%, even more preferably of 8-12% and most preferably of 10%.
  • the serum component may be replaced by any of several standard serum replacement mixtures which typically include insulin, albumin and lecithin or cholesterol.
  • a "culture vessel” is any vessel which is suitable for growing cells in a culture medium, in particular selected from, but not limited to, agar, matrigel and collagen, either in fluid phase or adhered to an interior surface of the container.
  • Types of such specialized vessels include roller bottles, spinner flasks, petri dishes and tissue flasks.
  • Culture vessels are designed to be incubated in temperature, humidity and gas controlled environments to facilitate maximum cell or tissue growth.
  • a layer of cell culture medium or agar covers the growing surface.
  • the portion of the vessel not utilized as a growing surface encloses the interior gaseous environment which surrounds the cell culture.
  • Cells, tissues, microorganisms and the like typically are introduced into the interior of cell culture vessels through an opening in the vessel. After introduction of the cells the opening may be closed such that the cells are not in contact with the environment during the culturing of the cells.
  • the culture vessel is treated for tissue culture, which means that the surface of the culture vessel is treated such that cells which usually grow in an adherent state grow adherently, but cells which grow in suspension do not adhere or adhere only loosely.
  • tissue culture means that the surface of the culture vessel is treated such that cells which usually grow in an adherent state grow adherently, but cells which grow in suspension do not adhere or adhere only loosely.
  • Such treatment may involve the irradiation of the vessel or the coating of the vessel, for example with a special plastic, polymer or nanostructure or with proteins of the extracellular matrix.
  • Such vessels can comprise tissue culture dishes and tissue culture flasks and are available from different suppliers such as Becton Dickinson, Greiner, Sigma and TPP.
  • the present invention also relates to a process for the production of cells exhibiting a multipotent, preferably a multipotent, stem cell character, wherein a process according to the above is carried out.
  • the present invention also relates to a process for improving the expansion of stem cells in vitro, wherein a process according to the present invention is carried out.
  • the present invention provides the advantage of prolonging expansion of stem cells, since the present invention keeps the cells to be expanded in a dedifferentiated status.
  • the present invention also relates to a process for the rejuvenation of aged cells, wherein a process according to the present invention is carried out.
  • the present invention also relates to a process for inducing the dedifferentiation of cells, wherein a process according to the present invention is carried out and wherein in particular the cells to be reprogrammed are differentiated cells, in particular lineage-committed cells.
  • the present invention also relates to a process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.
  • the present invention also relates to an in vivo method for reprogramming recipient cells of a mammal which employ the reprogramming mRNA molecules as identified above for the in vitro embodiment of the present invention.
  • the present invention relating to the process for reprogramming recipient cells of a mammal in vivo thereby foresees to introduce the reprogramming mRNA molecules directly into at least one cell of a recipient mammal that means into at least one recipient cell by suitable means such as gene gun insertion.
  • suitable means such as gene gun insertion.
  • Such a process allows the production of a mammal in particular a human being which has at least one reprogrammed cell.
  • this embodiment of the present invention provides terrifically improved therapeutic application, in particular in the regenerative medicine and/or in replacement therapy.
  • the present invention relates to a method of treating a mammal, in particular human being wherein reprogramming mRNA molecules are introduced into at least one cell of the recipient mammal and wherein the reprogrammed mRNA molecules are encoded at least by encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.
  • the present invention also relates to a multipotent, in particular a pluripotent, stem cell prepared according to any one of the methods of the present invention.
  • the reprogrammed cells according to the present invention are preferably multipotent, in particular pluripotent stem cells.
  • the cells obtained according to the present invention are distinguished from the cells used as a starting material in step a) of the present invention by lack of one or more markers. These cells may in a preferred embodiment be also characterized by a particular methylation pattern, by the expression of oct4, sox2, nanog, hTERT or klf4.
  • oct4 which is not found in somatic cells like fibroblasts, becomes expressed after transfecting mRNA (klf4, sox2 and oct4) in human fibroblasts, by improved growth potential; and by increased differentiation potential.
  • mRNA klf4, sox2 and oct4
  • the reprogrammed cells obtained by the present processs may preferably be characterized by the expression or non-expression of certain surface markers.
  • These surface markers are usually given a cluster of differentiation (CD) designation which describes groups of immunophenotypical surface characteristics of cells.
  • CD molecules are membrane-bound glycoproteins which are recognized by a cluster of monoclonal antibodies that display the same cellular reactivity.
  • FACS fluorescence-activated cell sorter
  • Methods to identify cells according to the present invention are methods to detect cell-specific proteins, methods to detect cell-specific transcription factors or methods to detect physiological or morphological changes.
  • Reprogrammed cells according to the present invention may be used for therapeutic, diagnostic or scientific purposes.
  • these cells may be used in regenerative medicine and/or for replacement therapy.
  • cell not only refers to a single cell but also encompasses a cell line, a cell population or a cell clone.
  • stem cells refers to cells which have retained the capacity to proliferate and differentiate into one or different cell types.
  • Stem cells created in accordance with the present invention are preferably pluripotent stem cells, i.e. stem cells which have retained the capacity to differentiate into distinct cell lineages and cell types or multipotent stem cells, retaining a more restricted differentiation potential.
  • stem cells in accordance with the invention does not comprise human embryos. Furthermore, it is understood that the term “stem cells” does not comprise pluripotent stem cells which have been directly derived from a human embryo. Embryonic stem cells which have been derived from publicly available and previously established stem cell lines are understood to fall within the meaning of the term “stem cells” as used by the present invention.
  • a “stem cell”, as used herein, refers to any self-renewing pluripotent cell or multipotent cell or progenitor cell or precursor cell that is capable of differentiating into one or multiple cell types.
  • Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited growth potential.
  • Stem cells include those that are capable of differentiating into cells of osteoblast lineage, a mesenchymal cell lineage (e. g. bone, cartilage, adipose, muscle, stroma, including hematopoietic supportive stroma, and tendon).
  • "Differentiate” or “differentiation”, as used herein, refers to the process by which precursor or progenitor cells (i.
  • differentiate cells differentiate into specific cell types, e. g., osteoblasts.
  • Differentiated cells can be identified by their patterns of gene expression and cell surface protein expression.
  • “Dedifferentiate” or “dedifferentiation”, as used herein, refers to the process by which lineage-committed cells (e. g., myoblasts or osteoblasts) reverse their lineage commitment and become precursor or progenitor cells (i. e., multipotent or pluripotent stem cells).
  • lineage-committed cells e. g., myoblasts or osteoblasts
  • precursor or progenitor cells i. e., multipotent or pluripotent stem cells.
  • Dedifferentiated cells can for instance be identified by loss of patterns of gene expression and cell surface protein expression associated with the lineage committed cells.
  • Lineage-committed cell refers to any cell that has or will differentiate into a particular cell type or related cell types.
  • Lineage committed cells include, for example, osteoblasts, myoblasts, chrondrocytes, and adipocytes.
  • Totipotent stem cells are able to create all cell types of the body, including placental cells.
  • the earlier stage foetal stem cells are considered totipotent, as well as the fertilised egg. They also have the ability to replicate in unlimited numbers without losing their potential.
  • Pluripotent stem cells are able to create cells of all three germ layer, namely the ecto-, endo- and mesoderm. They also have the ability to replicate in unlimited numbers without losing their potential.
  • Multipotent stem cells are able to produce cells of one or more germ layers or several types of tissues. They often have an already limited self-renewal ability.
  • Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited growth potential.
  • Progenitor cells can differentiate into one or more cell types but have a limited growth potential.
  • Adult stem cells are stem cells derived from an adult organism and might be multipotent or pluripotent.
  • Embryonic stem cells are derived from the inner mass of a blastula and are pluripotent. Embryonic stem cells are unique because they can develop into nearly all cell types, an attribute called pluripotency. But to access these cells, researchers must destroy a viable embryo. In this patent we are describing a way to create cells, with the characteristics of embryonic stem cells, without the need to destroy embryos or the use of embryonic stem cells.
  • IPS cells are pluripotent stem cells artificially derived from non-pluripotent cells, including somatic cells, adult multipotent stem cells or progenitor cells. In principal every cell containing a nuclei can be used as source for IPS cells.
  • sequence listing show the prior art DNA sequences encoding the mRNA nucleotide sequence molecules used in the present invention: Table 1 SEQ ID No. gene accession-number length 1 hNanog NM_024865 2098 2 mNanog NM_028016 1356 3 rNanog NM_001100781 2358 4 hSox2 NM_003106 2518 5 mSox2 NM_011443 2457 6 rSox2 NM_001109181 2323 7 hOct4 NM_002701 1411 8 mOct4 NM_013633 1346 9 hKlf4 NM_004235 2949 10 mKlf4 NM_010637 3057 11 rKlf4 NM_053713 2393 12 hTERT NM_198253 4018 13 mTert ENSMUSG00000021611 4237 14 rTERT NM_053423 3378 15 hRon
  • NM and ENSMUSG refer to the NM(NCBI)- and ENSMUSG-accession numbers as given under the publically available website http://www.ncib.nlm.nih.gov and http://www.ensembl.org.
  • SEQ ID No. 17 and 18 show the DNA sequence of primers used for cloning the human Nanog gene.
  • SEQ ID No. 19 and 20 show the DNA sequence of primers used for cloning the human Klf4 gene.
  • SEQ ID No. 21 and 22 show the DNA sequence of primers used for cloning the human Sox2 gene.
  • SEQ ID No. 23 and 24 show the DNA sequence of primers used for cloning the human Oct4 gene.
  • SEQ ID No. 25 and 26 show the DNA sequence of primers used for cloning the human Tert gene.
  • SEQ ID No. 27 and 28 show the DNA sequence of primers used for cloning the GFP gene.
  • the primers used are listed in Table 2.
  • Table 2 Name gen New digest sites for restriction enzymes Primer sequence 5'-3' Product size Nanog_human XbaI & NotI SEQ ID No. 17 918 bp Nanog_human SpeI & ClaI SEQ ID No. 18 Klf4_human XbaI & NotI SEQ ID No. 19 637 bp Klf4_human HindIII & ClaI SEQ ID No. 20 Sox2_human XbaI & BamHI SEQ ID No. 21 996 bp Sox2_human HindIII & ClaI SEQ ID No. 22 Oct4_human XbaI & NotI SEQ ID No.
  • a PCR for obtaining the desired digest sites was carried out with the Platinum Taq-Polymerase (Invitrogen).
  • Coating recommendations (0.3 ⁇ g/ ⁇ l) is of course dependant on the cell type that you are using to generate iPS. It is recommended to coat (not gel!) plastics for hESC culture using 1 ug Matrigel/ ⁇ l. Use plates immediately or store for max 7 days at 4°C covered with serum-free medium under aseptical conditions (sealed).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP08400048.8A 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status Not-in-force EP2192174B1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES08400048.8T ES2561949T3 (es) 2008-11-21 2008-11-21 Reprogramación de células hacia un estado pluripotente
EP08400048.8A EP2192174B1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status
EP14192115.5A EP2881461A1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status
US13/130,093 US20110236978A1 (en) 2008-11-21 2009-11-17 Reprogramming cells toward a pluripotent state
PCT/EP2009/008170 WO2010057614A1 (en) 2008-11-21 2009-11-17 Reprogramming cells toward a pluripotent state
JP2011536768A JP2012509072A (ja) 2008-11-21 2009-11-17 分化万能性状態への細胞の再プログラミング

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08400048.8A EP2192174B1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP14192115.5A Division-Into EP2881461A1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status
EP14192115.5A Division EP2881461A1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status

Publications (2)

Publication Number Publication Date
EP2192174A1 true EP2192174A1 (de) 2010-06-02
EP2192174B1 EP2192174B1 (de) 2015-11-11

Family

ID=40456300

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14192115.5A Withdrawn EP2881461A1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status
EP08400048.8A Not-in-force EP2192174B1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14192115.5A Withdrawn EP2881461A1 (de) 2008-11-21 2008-11-21 Umprogrammierung von Zellen zu einem pluripotenten Status

Country Status (5)

Country Link
US (1) US20110236978A1 (de)
EP (2) EP2881461A1 (de)
JP (1) JP2012509072A (de)
ES (1) ES2561949T3 (de)
WO (1) WO2010057614A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236978A1 (en) * 2008-11-21 2011-09-29 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V. Reprogramming cells toward a pluripotent state
EP2418273A4 (de) * 2009-04-10 2013-07-10 Obschestvo S Ogranichennoi Otvetstvennostyu Lab Kletochnykh T Verfahren zur herstellung pluripotenter zellen
EP2773380A2 (de) * 2011-11-03 2014-09-10 UCL Business Plc. Verfahren zur dedifferenzierung einer zelle
WO2022135584A1 (zh) * 2020-12-25 2022-06-30 中国农业大学 白藜芦醇在电穿孔转染细胞中的应用及电转液

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252122A1 (en) * 2011-01-05 2012-10-04 Sangamo Biosciences, Inc. Methods and compositions for increasing production of induced pluripotent stem cells (ipscs)
US8935421B2 (en) 2011-08-18 2015-01-13 International Business Machines Corporation System and method for stream processing
US8806055B2 (en) 2011-08-18 2014-08-12 International Business Machines Corporation System and method for stream processing utilizing totipotent morphogenic stem cells
US8660981B2 (en) 2011-08-18 2014-02-25 International Business Machines Corporation System and method for hierarchical stream processing
US8984329B2 (en) 2011-08-18 2015-03-17 International Business Machines Corporation System and method for stream processing utilizing multipotent morphogenic stem cells
ES2827207T3 (es) * 2011-12-01 2021-05-20 R Bio Co Ltd Composición de medio de cultivo de rejuvenecimiento de células madre
RU2691027C2 (ru) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10155929B2 (en) 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
DK2850179T3 (da) * 2012-05-13 2019-06-17 Allele Biotechnology & Pharmaceuticals Inc Feeder-cellefri afledning af human-inducerede pluripotente stamceller med syntetisk messenger-rna
EP2914728B1 (de) 2012-11-01 2020-07-08 Factor Bioscience Inc. Verfahren und produkte zur expression von proteinen in zellen
KR101588394B1 (ko) 2013-05-09 2016-01-25 라정찬 줄기세포의 재생능 향상을 위한 배지 조성물 및 이를 이용한 줄기세포의 배양방법
JP6676260B2 (ja) * 2013-10-17 2020-04-08 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN105940110A (zh) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 用于核酸产生和递送的方法和产品
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11286454B2 (en) * 2015-08-31 2022-03-29 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4232563A4 (de) * 2020-10-26 2024-12-04 University of Massachusetts Verfahren und zusammensetzungen zur behandlung von muskelerkrankungen mit ipsc-induzierten menschlichen skelettmuskelstammzellen
CN113481150B (zh) * 2021-06-11 2023-07-04 南方医科大学 Egfr抑制剂在提高精原干细胞重编程效率中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020759A1 (en) 2004-07-15 2007-01-25 Primegen Biotech Llc Therapeutic reprogramming of germ line stem cells
US20070254884A1 (en) 2003-11-10 2007-11-01 Shuibing Chen Compositions and Methods for Inducing Cell Dedifferentiation
WO2008087442A1 (en) * 2007-01-19 2008-07-24 Evocell Limited Biological materials and uses thereof
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
EP2072618A1 (de) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Verwendung von RNA zur Neuprogrammierung von Körperzellen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080068850A (ko) * 2005-10-14 2008-07-24 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
CN101864392B (zh) * 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
JP2007228815A (ja) * 2006-02-27 2007-09-13 Gifu Univ 胚性幹細胞の維持方法
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
US8298825B1 (en) * 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
EP2881461A1 (de) * 2008-11-21 2015-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Umprogrammierung von Zellen zu einem pluripotenten Status
US8048675B1 (en) * 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254884A1 (en) 2003-11-10 2007-11-01 Shuibing Chen Compositions and Methods for Inducing Cell Dedifferentiation
US20070020759A1 (en) 2004-07-15 2007-01-25 Primegen Biotech Llc Therapeutic reprogramming of germ line stem cells
WO2008087442A1 (en) * 2007-01-19 2008-07-24 Evocell Limited Biological materials and uses thereof
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
EP2072618A1 (de) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Verwendung von RNA zur Neuprogrammierung von Körperzellen
WO2009077134A2 (en) 2007-12-14 2009-06-25 Johannes Gutenberg-Universität Mainz Use of rna for reprogramming somatic cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"RENOWNED STEM CELL RESEARCHER JEANNE F. LORING HEADS NEW CENTER AT SCRIPPS RESEARCH INSTITUTE", NEWSWISE, 26 March 2008 (2008-03-26), pages 1 - 2, XP003036033, Retrieved from the Internet <URL:HTTP://WWW.NEWSWISE.COM/ARTICLES/RENOWNED-STEM-CELL-RESEARCHER-JEANNE-F-LORING-HEADS-NEW-CENTER-AT-SCRIPPS-RESEARCH-INSTITUTE>
ALTSCHUL, S.F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403
ALTSCHUL, S.F. ET AL., NUCLEIC ACID RES., vol. 25, 1997, pages 3389 - 3402
DEJOSEZ MARION ET AL: "Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells (vol 133, pg 1162, 2008)", CELL, vol. 134, no. 4, August 2008 (2008-08-01), pages 692, XP009114640, ISSN: 0092-8674 *
JAENISCH RUDOLF ET AL: "Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming", CELL, vol. 132, no. 4, February 2008 (2008-02-01), pages 567 - 582, XP009114628, ISSN: 0092-8674 *
JEANNE F. LORING: "HUMAN STEM CELL MANUAL. A LABORATORY GUIDE", 2007, ELSEVIER LTD, article JEANNE F. LORING ET AL: "HUMAN EMBRYONIC STEM CELL CULTURE", pages: 3 - 17, XP003036032
OKITA ET AL., SCIENCE, vol. 322, no. 5903, 7 November 2008 (2008-11-07), pages 949 - 53
TAKAHASHI K ET AL: "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 126, no. 4, 25 August 2006 (2006-08-25), pages 663 - 676, XP003013968, ISSN: 0092-8674 *
YU JUNYING ET AL: "Induced pluripotent stem cell lines derived from human somatic cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 318, no. 5858, 21 December 2007 (2007-12-21), pages 1917 - 1920, XP009105055, ISSN: 1095-9203 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236978A1 (en) * 2008-11-21 2011-09-29 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V. Reprogramming cells toward a pluripotent state
EP2418273A4 (de) * 2009-04-10 2013-07-10 Obschestvo S Ogranichennoi Otvetstvennostyu Lab Kletochnykh T Verfahren zur herstellung pluripotenter zellen
EP2773380A2 (de) * 2011-11-03 2014-09-10 UCL Business Plc. Verfahren zur dedifferenzierung einer zelle
WO2022135584A1 (zh) * 2020-12-25 2022-06-30 中国农业大学 白藜芦醇在电穿孔转染细胞中的应用及电转液

Also Published As

Publication number Publication date
US20110236978A1 (en) 2011-09-29
JP2012509072A (ja) 2012-04-19
ES2561949T3 (es) 2016-03-01
EP2192174B1 (de) 2015-11-11
WO2010057614A1 (en) 2010-05-27
EP2881461A1 (de) 2015-06-10

Similar Documents

Publication Publication Date Title
EP2192174B1 (de) Umprogrammierung von Zellen zu einem pluripotenten Status
CA2872688C (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EP2861724B1 (de) Transkriptionsfaktor vermittelte programmierung zu megakaryozyten
Gao et al. Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs
KR20190018709A (ko) 혈액을 유도 만능 줄기세포로 리프로그래밍하기 위한 신규하고 효율적인 방법
US20130059286A1 (en) Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells
KR100832592B1 (ko) 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
KR102746585B1 (ko) 기저 상태 다능성의 유도 및 유지를 위한 플랫폼
Dai et al. Non-genetic direct reprogramming and biomimetic platforms in a preliminary study for adipose-derived stem cells into corneal endothelia-like cells
KR20160130260A (ko) 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
EP3828263A1 (de) Verfahren und kit zur herstellung von mesenchymalen stammzellen von klinischer qualität aus humaninduzierten pluripotenten stammzellen
CN103003416A (zh) 从小体积的外周血产生诱导性多潜能干细胞
EP2997130A2 (de) Feeder-freie ableitung von menschgemachten pluripotenten stammzellen mit synthetischer boten-rns
CN103088065B (zh) 一种能够大规模并快速高纯度地诱导间充质干细胞转决定成造血干细胞的方法
WO2021202898A1 (en) Methods of making pluripotent stem cells and uses thereof
Zhi et al. Elucidation of the pluripotent potential of bovine embryonic lineages facilitates the establishment of formative stem cell lines
US9163234B2 (en) Culture method
WO2015008275A1 (en) Methods for large scale generation of stem cells
CA2950582C (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EP3770249A1 (de) Verfahren zur dreidimensionalen kultivierung pluripotenter stammzellen
WO2024024561A1 (ja) ケラチノサイトを作製する方法、ケラチノサイトを連続培養するための培地キット、及びケラチノサイト
KR102076223B1 (ko) 역분화 줄기세포의 지속적인 계대배양을 통한 중간엽 줄기세포로의 분화방법
WO2008070258A2 (en) Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells
KR20180112547A (ko) 역분화 줄기세포의 지속적인 계대배양을 통한 중간엽 줄기세포로의 분화방법
KR20190092898A (ko) 한국인 호발성 cyp 유전형을 포함하는 유도만능줄기세포주

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17P Request for examination filed

Effective date: 20101202

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20110222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140123

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150203

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BROWN, JEREMY

Inventor name: ARNOLD, ANTJE

Inventor name: STOLZING, ALEXANDRA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150626

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 760481

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008041099

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2561949

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160301

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160211

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151130

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160311

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008041099

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

26N No opposition filed

Effective date: 20160812

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20081121

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151121

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20170710

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 760481

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151111

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20181122

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20181121

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20181218

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191121

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191121

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191122

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20211117

Year of fee payment: 14

Ref country code: GB

Payment date: 20211123

Year of fee payment: 14

Ref country code: FR

Payment date: 20211119

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20211130

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20221121

Year of fee payment: 15

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 760481

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221121

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008041099

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221121